

## ATHEROSCLEROSIS IN MONOGENIC FAMILIAL HYPERCHOLESTEROLAEMIA VERSUS POLYGENIC HYPERCHOLESTEROLAEMIA

Mahtab Sharifi<sup>1,2</sup>, Angela Gallivan<sup>2</sup>, Darren Harvey<sup>2</sup>, Jackie Cooper<sup>1</sup>, Ka Wah Li<sup>1</sup>, Martha Futema<sup>1</sup>, Steve E. Humphries<sup>1</sup>, Devaki Nair<sup>2</sup>

<sup>1</sup> Centre for Cardiovascular Genetic, University College London, The Rayne Institute, University Street, London, UK

<sup>2</sup> Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, Pond Street, London, UK

**Introduction:** The aim of this study was to assess the degree of atherosclerosis in monogenic Familial Hypercholesterolaemia (FH) patients versus individuals with a clinical diagnosis of FH but with no detectable mutation (ie with polygenic hypercholesterolaemia).

**Method:** Carotid Intima Media Thickness (cIMT) was measured by B-mode ultrasound in the common carotid artery, bifurcation and internal carotid artery in 86 individuals (53 females and 33 male) with a clinical diagnosis of FH (LDL-C mean±SD: 5.8±1.3 mmol/l). 56 patients had monogenic FH with a mutation in the *LDLR* or *APOB* gene and 30 patients had no mutation and had a score in the top two quartiles of a six LDL-C-raising SNPs gene score.

**Results:** The monogenic patients were younger than polygenic individuals (50±14 years vs 57±12 years,  $p=0.03$ ). There was no significant difference in total cholesterol level, LDL-C and HDL-C between the two groups. Triglyceride level was significantly higher in the polygenic compared to the monogenic group (1.6±0.7 mmol/l vs 1.2±0.5 mmol/l,  $p=0.01$ ). After adjustment for age and gender, the mean of all the cIMT measurements was significantly higher in monogenic than polygenic patients [0.74 mm (0.7-0.79) vs 0.66 mm (0.61-0.72),  $p=0.039$ ].

**Conclusion:** The severity of atherosclerosis as measured by cIMT is higher in monogenic FH individuals than the polygenic group. While LDL-C levels need to be reduced in both groups, the greater degree of carotid atherosclerosis supports aggressive management of their LDL-C levels with potent statins and other LDL-C lowering modalities in combination.